Inclusion Criteria:

Men age 18 years of age or older who have HRPC are eligible for this study based on the
following inclusion criteria:

1. Histologically confirmed adenocarcinoma of the prostate.

2. Progressive hormone refractory locally advanced or metastatic disease.

- (Definition of HRPC): Clinical or serological evidence of disease progression
despite adequate anti-androgen therapy, documented by castrate levels of serum
testosterone (<50 ng/mL).

- Patients on medical castration therapy should continue on treatment to maintain
castrate levels of serum testosterone. Patients receiving anti-androgen or
estrogen therapy should either be maintained on it, or have documented
progression 4 weeks after withdrawal of all agents (except nilutamide and
bicalutamide), which requires 6 weeks.

3. Disease Progression, documented by any of the following:

- PSA Progression, documented by an elevated PSA level (>5 ng/mL), which has risen
serially from the baseline PSA value (PSA value #1) on two occasions, each at
least 1 week apart (these will be considered PSA values #2 and #3). (Note: if
the level of PSA value #3 is less than the level of PSA value #2, a subsequent
PSA value must be obtained (PSA value #4) at least 1 week after PSA value #3 was
measured. In order for this event to be considered a PSA progression, the level
of this final PSA value (PSA value #4) must be greater than the PSA level that
was observed for PSA value #2.

- Progressive metastatic prostate carcinoma, documented by computed tomography
(CT), magnetic resonance imaging (MRI), or radiograph of non osseous lesions
(see Section 7.2).

- Bone Scan Progression, documented by the appearance of at least one or more new
lesions that are not believed to be secondary to tumor flare phenomenon.

4. Patients with bone only disease must have a PSA level >=5 ng/mL; patients with stable
lesions must have evidence of PSA progression. Patients must have radiographically or
clinically demonstrable metastatic disease.

5. Receipt of either 1 or 2 previous chemotherapy regimens; one of these regimens must
have included docetaxel.

6. ECOG performance status of 0-2.

7. Adequate bone marrow function, defined by: white blood cells >=3,500/uL, hemoglobin
>=8 g/dL, platelet count >=100,000/uL.

8. Adequate renal function, defined by: serum creatinine <1.8 mg/dL, or calculated or
measured creatinine clearance (GFR) of >=60 cc/min. Patients with a creatinine
clearance of >30 mL/min but <60 mL/min may also be enrolled, but will require an
initial adjusted dose (see Section 5.1)

9. Adequate hepatic function, defined by: total bilirubin <1.5 x the upper limit of
normal, AST <2 x the upper limit of normal.

10. Patients must be able to comprehend the nature of the study and provide written
informed consent.

11. Partners of women of childbearing potential must use effective contraception while on
treatment and for at least 3 months thereafter. Women of childbearing potential
include females who have experienced menarche and have not undergone successful
surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral
oophorectomy) or are not post-menopausal (i.e., amenorrhea >12 months).

12. Patients on bisphosphonate therapy (at the discretion of the investigator).

Exclusion Criteria:

1. History of other prior malignancy in the past 5 years (excluding resected basal cell
or squamous cell skin cancer).

2. History of second- or third-degree heart block, uncontrolled angina, uncontrolled
hypertension, or recent myocardial infarction or congestive heart failure (New York
Heart Association Class III-IV) within the past 6 months (see Appendix F)

3. Cerebral vascular accident within the past 6 months.

4. Peripheral neuropathy > grade 2 per Common Terminology Criteria for Adverse Events
(CTCAE) v3.0.

5. Patients with rising PSA but no demonstrable metastases.

6. Previous radiotherapy, outside of standard portals, utilized for prostate cancer (if
total amount of radiotherapy encompasses >25% of bone marrow containing osseous
regions).

7. Prior therapy with Strontium 90, Samarium 150, or other injectable therapeutic
radioisotopes.

8. History of prior allergic reaction to any vinca alkaloid.

9. Use of chemotherapy or investigational drugs within 4 weeks prior to the first dose
of study drug.

10. Treatment with ketoconazole, itraconazole, ritonavir, amprenavir, or indinavir within
4 weeks prior to the first dose of study drug.

11. Previous treatment with an anthracycline.

12. Patients who are unable to receive chemotherapy on a basis of once every three weeks
as a result of physical, environmental, or co existent medical problems.